JACC CardioOncology,
Год журнала:
2024,
Номер
7(1), С. 20 - 33
Опубликована: Дек. 3, 2024
Patients
with
lymphoma
are
at
high
risk
for
developing
heart
failure
(HF)
after
autologous
hematopoietic
cell
transplantation
(HCT).
More
accurate
determination
pre-HCT
may
facilitate
screening
and
prevention
of
HF.
The
aim
this
study
was
to
examine
the
association
between
clonal
hematopoiesis
indeterminate
potential
(CHIP)
HF
HCT
lymphoma.
This
a
retrospective
cohort
861
patients
who
underwent
2010
2016
City
Hope
Comprehensive
Cancer
Center.
Targeted
DNA
sequencing
performed
determine
presence
CHIP
(variant
allele
frequency
≥
2%).
primary
outcome
interest
5-year
cumulative
incidence
de
novo
Other
outcomes
included
overall
cause-specific
mortality.
Overall,
186
(21.7%
cohort)
had
least
1
variant,
59
(6.9%)
≥2
variants.
DNMT3A,
PPM1D,
TET2
were
most
frequently
mutated
genes.
significantly
higher
in
compared
those
without
(13.8%
vs
4.7%;
P
<
0.001;
sub-distribution
hazard
ratio
[sHR]:
2.48;
95%
CI:
1.32-4.68);
increased
by
variant
frequency:
0-2%
(4.7%),
2-10%
(11.7%),
>10%
(18.5%),
0.001.
worse
survival
HCT,
(63.4%
80.3%;
0.001),
due
primarily
nonrelapse
mortality
(subdistribution
HR:
5.37;
2.34-12.35).
highly
prevalent
associated
HCT.
These
findings
highlight
role
as
novel
biomarker
target
intervention
improve
Journal of Clinical Medicine,
Год журнала:
2024,
Номер
13(20), С. 6084 - 6084
Опубликована: Окт. 12, 2024
The
most
common
causes
of
morbidity
and
mortality
in
the
myeloproliferative
neoplasms
(MPNs),
with
exception
myelofibrosis,
are
venous
arterial
thrombosis,
as
well
more
recently
discovered
cardiovascular
disease
(CVD).
Clonal
hematopoiesis
indeterminate
potential
(CHIP)
is
subclinical
finding
an
individual
somatic
mutations
that
also
found
clinically
overt
MPNs
other
myeloid
malignancies.
prevalence
"silent"
CHIP
increases
age.
can
transform
into
a
MPN
at
estimated
rate
0.5
to
1%
per
year.
It
likely,
therefore,
but
not
proven,
many,
if
all,
patients
had
antecedent
CHIP,
possibly
for
many
years.
Moreover,
both
individuals
asymptomatic
diagnosed
MPN,
develop
thrombotic
complications.
An
unexpected
remarkable
discovery
during
last
few
years
even
(as
MPNs)
significant,
independent
risk
factors
CVD.
This
review
discusses
up-to-date
information
on
types
complications
patients.
A
systemic
inflammatory
state
(that
often
subclinical)
likely
be
major
mediator
adverse
reciprocal
bone
marrow-cardiovascular
interplay
may
fuel
development
progression
MPNs,
including
its
vascular
complications,
worsening
disease,
"vicious
cycle".
Translating
this
clinical
practice
hematologists
oncologists
who
treat
patients,
attention
should
now
paid
ensuring
controlled
minimized,
either
by
patient's
cardiologist
or
primary
care
physician
hematologist/oncologist
herself
himself.
intended
cover
aspects
thrombosis
accompanied
pathobiological
comments.
medRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2024,
Номер
unknown
Опубликована: Июль 31, 2024
Abstract
Age-associated
clonal
hematopoiesis
of
indeterminate
potential
(CHIP)
has
been
associated
with
increased
incidence
and
worse
prognosis
chronic
heart
failure.
CHIP
is
driven
by
somatic
mutations
in
hematopoietic
stem
progenitor
cells
(HSPC).
Mosaic
loss
the
Y
chromosome
(LOY),
most
common
mutation
blood
men,
also
correlates
expansion
myeloid
cells,
increases
age
was
experimentally
shown
to
lead
diffuse
cardiac
fibrosis
subsequent
failure
mice.
However,
prognostic
significance
LOY
as
well
its
interaction
patients
unknown.
We
investigated
prevalence
extent
two
CHIP-driver
DNMT3A
TET2
705
male
established
across
entire
spectrum
left
ventricular
ejection
fraction.
Both,
DNMT3A/TET2
mutations,
age,
co-occurred
27.1%
men
at
>
70
years.
an
independent
predictor
death
during
3-years
follow-up
The
co-occurrence
harboring
significantly
contributed
observed
mortality
carriers
mutations.
detrimental
effect
on
confirmed
a
validation
cohort
ischemic
disease.
scRNA
sequencing
peripheral
showed
profibrotic
signaling
monocytes
elevated
markers
monocyte
mediated
inflammation
remodeling
(S100A8,
TLR2,
CLEC4D)
reduced
expression
TGF-β
inhibiting
genes
(SMAD7,
TGIF2).
proinflammatory
phenotype
further
amplified
simultaneously
who
displayed
heightened
alarmins
HMGB2)
interferon
related
(IFNGR1,
TRIM56,
CD84)
compared
without
Thus,
age-associated
acquisition
mortality,
emerging
all-cause
function.
European Heart Journal,
Год журнала:
2024,
Номер
unknown
Опубликована: Окт. 7, 2024
The
increased
sensitivity
of
novel
DNA
sequencing
techniques
has
made
it
possible
to
identify
somatic
mutations
in
small
circulating
clones
haematopoietic
stem
cells.
When
the
mutation
affects
a
'driver'
gene,
mutant
clone
gains
competitive
advantage
and
potential
expand
over
time,
phenomenon
referred
as
clonal
haematopoiesis
(CH),
which
is
emerging
new
risk
factor
for
various
non-haematological
conditions,
most
notably
cardiovascular
disease
(e.g.
heart
failure).
Dilated
cardiomyopathy
(DCM)
form
non-ischaemic
failure
that
characterized
by
heterogeneous
aetiology.
first
evidence
arising
CH
plays
an
important
role
course
patients
with
DCM,
strong
association
multiple
aetiologies
DCM
been
described
inflammation,
chemotherapy,
atrial
fibrillation).
myocardial
inflammation
induced
may
be
trigger
development
already
susceptible
heart,
e.g.
presence
genetic
variants,
environmental
triggers,
comorbidities.
Studies
investigating
pathogenesis
are
expected
increase
rapidly.
To
move
field
forward,
will
report
methodology
results
standardized
manner,
so
can
combined
compared.
accurate
measurement
provide
guidance
specific
(anti-inflammatory)
therapies,
driver
genes
prime
inflammasome
pathway.
JACC CardioOncology,
Год журнала:
2024,
Номер
7(1), С. 20 - 33
Опубликована: Дек. 3, 2024
Patients
with
lymphoma
are
at
high
risk
for
developing
heart
failure
(HF)
after
autologous
hematopoietic
cell
transplantation
(HCT).
More
accurate
determination
pre-HCT
may
facilitate
screening
and
prevention
of
HF.
The
aim
this
study
was
to
examine
the
association
between
clonal
hematopoiesis
indeterminate
potential
(CHIP)
HF
HCT
lymphoma.
This
a
retrospective
cohort
861
patients
who
underwent
2010
2016
City
Hope
Comprehensive
Cancer
Center.
Targeted
DNA
sequencing
performed
determine
presence
CHIP
(variant
allele
frequency
≥
2%).
primary
outcome
interest
5-year
cumulative
incidence
de
novo
Other
outcomes
included
overall
cause-specific
mortality.
Overall,
186
(21.7%
cohort)
had
least
1
variant,
59
(6.9%)
≥2
variants.
DNMT3A,
PPM1D,
TET2
were
most
frequently
mutated
genes.
significantly
higher
in
compared
those
without
(13.8%
vs
4.7%;
P
<
0.001;
sub-distribution
hazard
ratio
[sHR]:
2.48;
95%
CI:
1.32-4.68);
increased
by
variant
frequency:
0-2%
(4.7%),
2-10%
(11.7%),
>10%
(18.5%),
0.001.
worse
survival
HCT,
(63.4%
80.3%;
0.001),
due
primarily
nonrelapse
mortality
(subdistribution
HR:
5.37;
2.34-12.35).
highly
prevalent
associated
HCT.
These
findings
highlight
role
as
novel
biomarker
target
intervention
improve
